Navigation Links
Clet Niyikiza, Merrimack's Executive Vice President of Development, to Present at BioVisionAlexandria 2010
Date:4/14/2010

Merrimack Pharmaceuticals, Inc. announced today that Clet Niyikiza, Ph.D., Executive Vice President of Development, will present at the BioVisionAlexandria 2010 conference as part of the panel, titled Cancer Care and Prevention: Novel Approaches.

Cambridge, MA (PRWEB) April 14, 2010 -- Clet Niyikiza, Ph.D., Executive Vice President of Development at Merrimack Pharmaceuticals, Inc., will present at the BioVisionAlexandria 2010 conference in Alexandria, Egypt.

The theme of this year’s fifth international biennial conference, put on by BioVision Alexandria, is New Life Sciences: Future Prospects. The goal of the conference is to get the greatest minds in industry, science, policy-making and civil society to identify and explore key areas in the field of life sciences that have the potential to serve a number of people across continents and cultures. Also featured in the conference is a Nobel Day where recipients of the Nobel Prize discuss the impact of their work and their future vision for the life sciences industry.

Dr. Niyikiza is speaking as part of a panel discussion in the Health portion of the conference which is built around the three major themes of Health, Food and Agriculture and Environment. The panel, titled Cancer Care and Prevention: Novel Approaches, takes place on Wednesday, April 14 from 3:30pm – 5:00pm.

About Merrimack
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and development of novel medicines for the treatment of cancer and inflammation. The Company is advancing a robust pipeline of engineered therapeutics paired with molecular diagnostics. Merrimack’s first two oncology candidates, MM-121, partnered with sanofi-aventis, and MM-111, are in Phase 1 clinical testing with multiple pre-clinical development and research stage programs in the pipeline. MM-121 and MM-111 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The Company’s proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, integrates the fields of engineering, biology and computing to enable mechanism-based model driven discovery and development of both therapeutics and diagnostics. Merrimack is a privately-held company based in Cambridge, Massachusetts. For additional information, please visit http://www.merrimackpharma.com.

Contact: Kathleen Petrozzelli, Corporate Communications, 617-441-1043, Betsy Raymond Stevenson, 860-984-1424, RaymondStevenson Healthcare Comms

###

Read the full story at http://www.prweb.com/releases/2010/04/prweb3868554.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development
2. Merrimack Pharmaceuticals Recognized for Innovative Talent Management in HR Executive Magazine's ‘Best HR Ideas for 2010' Issue
3. UPDATE: Appeal of Lawsuit by Former Chief Executive Officer- Reinstated; and Sanctions Order Vacated
4. Appeal of Lawsuit by Former Chief Executive Officer- Reinstated; and Sanctions Order Vacated
5. BioSoteria eLearning Executive Michelle Flewell Selected for Accreditation Council
6. FMC Agricultural Products Executive Bob Trogele Speaks to the Iowa Agribusiness Showcase & Conference
7. Amicus Therapeutics Board of Directors Names Chief Executive Officer John F. Crowley Chairman of the Board
8. Fibrocell Science, Inc. Names David Pernock Chief Executive Officer
9. Glycos Biotechnologies Appoints Chief Executive Officer
10. Biofuels Technology Leader Qteros Names Industry Veteran John McCarthy President and Chief Executive Officer
11. Marrone Bio Innovations Announces Two New Executive Appointments
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Clet Niyikiza, Merrimack's Executive Vice President of Development, to Present at BioVisionAlexandria 2010
(Date:6/23/2016)... 2016  The Prostate Cancer Foundation (PCF) is pleased to announce ... cures for prostate cancer. Members of the Class of 2016 were selected from ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software ... State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , ... Tremblay, President and COO of STACS DNA. “In further expanding our capacity as a ...
(Date:6/23/2016)... 2016 Andrew D ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a division ... tuned and optimized exclusively for Okuma CNC machining centers at The International Manufacturing ... collaboration among several companies with expertise in toolholding, cutting tools, machining dynamics and ...
Breaking Biology Technology:
(Date:3/23/2016)... 2016 Einzigartige ... und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler Kommunikationsdienste, ... SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie einzusetzen. ... Möglichkeit angeboten, im Rahmen mobiler Apps neben ...
(Date:3/22/2016)... , PROVO and ... -- Newborn Screening Ontario (NSO), which operates the highest ... for molecular testing, and Tute Genomics and UNIConnect, leaders ... technology respectively, today announced the launch of a project ... sequencing (NGS) testing panel. NSO has ...
(Date:3/18/2016)... -- --> --> Competitive ... Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance & Detection Systems ... security market and the continuing migration crisis in the ... has led visiongain to publish this unique report, which ... defence & security companies in the border security market ...
Breaking Biology News(10 mins):